GlassScriptPhysician profile
Kelly R Link
NPI 1942632344
$10,927.66
in general payments reported to CMS, 2019-2025
19 companies · $2,757 in 2025
The $2,757 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,140 · 2023: $2,762 · 2024: $2,267 · 2025: $2,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,699 · Travel and Lodging: $925 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,698.77 |
| Travel and Lodging | $925.41 |
| Education | $163.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $8,999.72 | 2022-2025 | Inspire |
| Harmony Biosciences LLC | $331.95 | 2024-2025 | |
| Axsome Therapeutics, INC. | $287.02 | 2023-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $186.00 | 2024-2025 | Lumryz |
| United Therapeutics Corporation | $167.74 | 2022-2024 | Tyvaso |
| Lilly USA, LLC | $126.00 | 2022-2025 | Zepbound |
| Jazz Pharmaceuticals INC. | $99.01 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $97.55 | 2024-2025 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $97.08 | 2023-2024 | Yupelri |
| Amgen INC. | $89.53 | 2023-2024 | Tezspire |
| Irhythm Technologies, INC. | $87.99 | 2024 | Zio Monitor, Zio Xt Patch |
| Mallinckrodt Hospital Products INC. | $75.30 | 2023-2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $65.12 | 2023-2024 | Airsupra, Fasenra |
| Idorsia Pharmaceuticals US INC | $51.23 | 2023-2024 | Quviviq |
| Inogen, INC. | $47.58 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41.79 | 2024 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.65 | 2023-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $21.46 | 2023 | Belsomra |
| Resmed Corp | $13.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.